This is consistent with genomic studies in humans living at high altitude where polymorphisms in both genes, EPAS-1 for HIF-2α, and EGLN1 for PHD2, are somewhat protecting from developing PAH in such hypoxic conditions (214–216). This evidence concerns the gene EGLN1 and pulmonary arterial hypertension.